Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cash, Cash Equivalents and Short-Term Investments (Tables)

Cash, Cash Equivalents and Short-Term Investments (Tables)

6 Months Ended

Jun. 30, 2019

Cash, Cash Equivalents and Short-Term Investments

Schedule of cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments consisted of the following (in thousands):


	June 30,		December 31,
	2019		2018
Cash	$	2,298	$	2,626
Money market funds		9,855		9,106
Government-sponsored enterprise securities		4,997		7,872
Corporate bonds and commercial paper		95,227		108,933
	$	112,377	$	128,537
Reported as:
Cash and cash equivalents	$	44,229	$	76,322
Short-term investments		68,148		52,215
	$	112,377	$	128,537

Schedule of cash equivalents and short-term investments including the securities with unrealized gains and losses

Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized
June 30, 2019	Cost		Gains		Losses		Fair Value
Government-sponsored enterprise securities	$	4,995	$	2	$	—	$	4,997
Corporate bonds and commercial paper		95,186		49		(8)		95,227
Total	$	100,181	$	51	$	(8)	$	100,224


			Gross		Gross
	Amortized		Unrealized		Unrealized
December 31, 2018	Cost		Gains		Losses		Fair Value
Government-sponsored enterprise securities	$	7,873	$	—	$	(1)	$	7,872
Corporate bonds and commercial paper		108,957		2		(26)		108,933
Total	$	116,830	$	2	$	(27)	$	116,805

Schedule of fair value and gross unrealized losses of the entity's investments in unrealized loss position

The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):


June 30, 2019	Fair Value		Unrealized Losses
Corporate bonds and commercial paper	$	43,278	$	(8)